 Pineault L, Valencia K, Buhay J, Brown A, Ziemnik S, Kelly M, Morgante J, Datta Mitra A, Yanamura L, Gilliland M, Ferea A, Kim J. ASCP explores the cancer biomarker testing navigator as a novel role to improve laboratory operations and workflows: A special report from the ASCP Biomarker Testing Navigator Project Team. Am J Clin Pathol. 2025 May 7:aqaf028. doi: 10.1093/ajcp/aqaf028. Epub ahead of print. PMID: 40329479. doi.org/10.1093/ajcp/aqaf028
0 Comments
ASCP has recently developed several CME activities on the topic of HER2-low and HER2-ultralow breast cancer:
Best Practices in HER2-low and HER2-ultralow Advanced Breast Cancer: IHC Testing and Interpretation Link: https://store.ascp.org/productlisting/productdetail?productId=176966209 Best Practices in HER2-low and HER2-ultralow Advanced Breast Cancer: Emerging Science and Current Treatment Link: https://store.ascp.org/productlisting/productdetail?productId=176989985 Best Practices in HER2-low and HER2-ultralow Advanced Breast Cancer: Reproducibility of Testing Link: https://store.ascp.org/productlisting/productdetail?productId=176990098 Congratulations to the collaborative efforts of ASCP and Q Synthesis for winning the 2025 Award for Outstanding Outcomes in CE Assessment! The project: “Building Knowledge and Skills in Biomarker Testing and Assessment of Pathological Response to Improve Care for Patients with Non-Small Cell Lung Cancer and Melanoma” was supported by an educational grant from BMS.  The Joint Commission and the National Association for Healthcare Quality Form Strategic Alliance to Advance Global Patient Safety and Healthcare Quality
(CHICAGO and OAKBROOK TERRACE, Illinois, November 19, 2024) – The Joint Commission and the National Association for Healthcare Quality (NAHQ) announce a strategic alliance to advance global healthcare Quality and safety for all. The alliance stems from a shared vision for safe, high-quality and equitable healthcare between NAHQ, the industry leader in defining Quality competencies and developing and certifying the healthcare Quality workforce, and The Joint Commission, the world’s premier and most recognized brand in standards-setting and accrediting body in healthcare. Read more about this here: www.jointcommission.org/resources/news-and-multimedia/news/2024/11/the-joint-commission-and-nahq-form-strategic-alliance/ Obesity Change Makers: National Quality Improvement Initiative to Improve Evidence-Based Care
Presented at ObesityWeek 2024 Learn more about this project here: clinicaloptions.com/content/qi-obesity QI Toolkit: clinicaloptions.com/activities/endocrinology-diabetes-metabolism/obesity-qi-tool-kit/17391-24775/info Preparing the Laboratory for Neoadjuvant Cancer Immunotherapy: Insights from a Pathology Learning Collaborative
American Journal of Clinical Pathology, Volume 162, Issue Supplement_1, October 2024, Page S125 doi.org/10.1093/ajcp/aqae129.277 Assessing the Feasibility of a Cancer Biomarker Testing Navigator in the Laboratory American Journal of Clinical Pathology, Volume 162, Issue Supplement_1, October 2024, Page S122 doi.org/10.1093/ajcp/aqae129.270 Impact of a PD-L1 Learning Collaborative: outcomes from a mixed-methods evaluation American Journal of Clinical Pathology, Volume 162, Issue Supplement_1, October 2024, Pages S143–S144 doi.org/10.1093/ajcp/aqae129.319 Integrating Biomarker Testing into EHR Systems: Implications for the Laboratory Based on Findings from a Multistakeholder Summit American Journal of Clinical Pathology, Volume 162, Issue Supplement_1, October 2024, Page S101 doi.org/10.1093/ajcp/aqae129.225 ASCP has released 3 CME activities to cover recent updates on pan-tumor HER2 testing in advanced solid tumors.
Updates in HER2-directed Therapies in Solid Tumors https://store.ascp.org/productlisting/productdetail?productId=173008379 HER2 Testing in Gynecologic Cancers and Implications for Treatment https://store.ascp.org/productlisting/productdetail?productId=173041833 HER2 Testing in Other Solid Tumors and Implications for Treatment https://store.ascp.org/productlisting/productdetail?productId=173042038
Scroll down to read each Tweet of this CME Tweetorial on pan-tumor HER2 testing!
Click on each Tweet below to open on Twitter: x.com/ASCP_Chicago/status/1840785569023995962 Claim CME here: store.ascp.org/productlisting/productdetail?productId=172789750
Claim CME here: store.ascp.org/productlisting/productdetail?productId=172789750
Here are a series of online CME/CE activities covering cancer biomarker testing and precision oncology in patients with actionable genomic alterations:
clinicaloptions.com/program/oncology/reshaping-care-biomarker-testing-in-solid-tumors/28010
Twitter (X) for CME!
Here is a CME Tweetorial on the topic of pan-tumor HER2 in advanced gynecologic cancers. Read through these threaded tweets: x.com/ASCP_Chicago/status/1826660024975782312 Claim CME credit here: t.co/iJjqlWc47f
|
